Journal of Clinical and Experimental Ophthalmology
Open Access
ISSN: 2155-9570
+44 1223 790975
ISSN: 2155-9570
+44 1223 790975
Aki Kato
Nagoya City University Graduate School of Medical Sciences,
1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi 467-8601
Japan
Research Article
Effect of a Single-Dose Regimen of Intravitreal Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration
Author(s): Sayaka Ikemori, Aki Kato, Tsutomu Yasukawa, Tomoaki Hattori, Miho Nozaki, Hiroshi Morita, Yoshio Hirano, Munenori Yoshida and Yuichiro OguraSayaka Ikemori, Aki Kato, Tsutomu Yasukawa, Tomoaki Hattori, Miho Nozaki, Hiroshi Morita, Yoshio Hirano, Munenori Yoshida and Yuichiro Ogura
Purpose: The purpose of this study was to demonstrate the effect of a single-dose regimen for treating AMD. Methods: Patients (mean age, 75.5 years; range, 60-86) were enrolled who had AMD with a baseline Logarithm of Minimum Angle of Resolution (logMAR) Best-Corrected Visual Acuities (BCVAs) of 0.15 to 1.30 treated with intravitreal ranibizumab as the primary treatment. Eleven eyes (11 patients) received the three-injection loading regimen (3+PRN), and 21 eyes (20 patients) received the single-injection regimen (1+PRN). The mean follow-up period was 16.0 months. In the maintenance phase, additional treatment was administered when subretinal or intraretinal fluid persisted or recurred, BCVA decreased, new subretinal or retinal hemorrhage was observed, or choroidal neovascularization enlarged. The BCVAs and central retinal thickness were measured.. View More»
DOI:
10.4172/2155-9570.1000221